Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Vascular endothelial growth factor (VEFG) stimulates tumor-associated angiogenesis, thereby making it a prime target for the development of anti-VEGF compounds. One such anti-VEGF drug, bevacizumab, has improved survival rates in some cancer trials. The key clinical trial data and reasons for some of the contrasting results seen in different patient studies are discussed.
With less than 10% of patients with metastatic renal cell cancer (RCC) surviving beyond 5 years, the management of this disease remains a therapeutic challenge. Conventional immune-based treatments are moderately successful, but complete disease remission has been observed using allogeneic stem-cell transplantation. Newer innovative approaches to maximize the graft-versus-tumor effect using this approach show promise in treating RCC.